Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 35.55%.

  • Catalyst Pharmaceuticals' EBITDA Margin rose 14500.0% to 35.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.63%, marking a year-over-year increase of 66200.0%. This contributed to the annual value of 33.34% for FY2024, which is 154100.0% up from last year.
  • Catalyst Pharmaceuticals' EBITDA Margin amounted to 35.55% in Q3 2025, which was up 14500.0% from 35.59% recorded in Q2 2025.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBITDA Margin peaked at 41.91% during Q4 2022, and registered a low of 29.96% during Q3 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 34.1% (2024), whereas its average is 30.55%.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EBITDA Margin crashed by -1191600bps in 2021 and then soared by 640600bps in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' EBITDA Margin stood at 24.08% in 2021, then soared by 74bps to 41.91% in 2022, then decreased by -25bps to 31.51% in 2023, then rose by 25bps to 39.49% in 2024, then fell by -10bps to 35.55% in 2025.
  • Its EBITDA Margin was 35.55% in Q3 2025, compared to 35.59% in Q2 2025 and 40.06% in Q1 2025.